Clinical Trials on Hormone Refractory Prostate Cancer in United Kingdom
Total 6878 results
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust and other collaboratorsRecruitingHormone Refractory Prostate CancerUnited Kingdom
-
Amunix, a Sanofi CompanyRecruitingHormone-refractory Prostate CancerAustralia, Spain, United Kingdom
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
Veeda OncologyBayerTerminatedHormone Refractory Prostate CancerUnited States
-
University of FloridaCureVacTerminated
-
CytRxCompletedHormone Refractory Prostate CancerUnited States
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
David M LubaroffUnited States Department of DefenseCompletedHormone Refractory Prostate CancerUnited States
-
Duke UniversityUnited States Department of DefenseCompletedMetastatic Hormone Refractory Prostate CancerUnited States
-
Queen's Medical CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedHormone Refractory Prostate CancerUnited States
-
Achieve Life SciencesTeva Pharmaceuticals USATerminatedHormone Refractory Prostate Cancer | Castrate-Resistant Prostate CancerFrance, United States, Spain, United Kingdom, Canada
-
Daniel George, MDNovartis PharmaceuticalsCompletedHormone Refractory Prostate CancerUnited States
-
DendreonCompletedHormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States
-
Merrion Pharmaceuticals, LLCCompletedHormone-Refractory Prostate CancerUnited States, Estonia, Latvia
-
CelgeneCompletedHormone Refractory Prostate CancerUnited States
-
Novartis PharmaceuticalsTerminatedHormone Refractory Prostate CancerUnited States
-
Astellas Pharma IncAstellas Pharma US, Inc.TerminatedProstatic Neoplasms | Hormone-Refractory Prostate CancerUnited States, Ireland, Australia, France, United Kingdom, Belgium, Germany, Netherlands, Poland, Spain
-
AgennixCompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States, United Kingdom, France, Italy, Israel, Germany, Hungary, Argentina, Russian Federation, Belgium, Croatia, Netherlands, Peru, Poland, Spain
-
Novartis PharmaceuticalsTerminatedHormone Refractory Prostate Cancer DiseaseUnited States
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States, Russian Federation
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone Refractory Prostate CancerUnited States, Canada
-
Novartis PharmaceuticalsCompletedMetastatic Hormone Refractory Prostate CancerUnited States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
-
Oxford BioMedicaMedSource LLCTerminatedHormone Refractory Prostate CancerUnited States
-
Genzyme, a Sanofi CompanyCompletedHormone-refractory Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate CancerUnited States
-
Sandy SrinivasWyeth is now a wholly owned subsidiary of Pfizer; American Society of Clinical... and other collaboratorsTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
Stanford UniversityTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
University of Michigan Rogel Cancer CenterNovartis; Aventis PharmaceuticalsCompletedHormone-Refractory Prostate CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bayer; Janssen, LP; Prostate Cancer Clinical Trials ConsortiumCompletedStage IV Prostate Adenocarcinoma | Hormone-refractory Prostate Cancer | Prostate Carcinoma Metastatic to the BoneUnited States
-
Northwestern UniversityRecruitingMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic CancerUnited States
-
DendreonCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateAustria, France, Netherlands, United Kingdom
-
Washington University School of MedicineBristol-Myers Squibb; ExelixisActive, not recruitingMetastatic Hormone Refractory Prostate CancerUnited States
-
GenesisCare USADendreonCompletedCastrate Refractory Metastatic Prostate Cancer (mCRPC)United States
-
University of OxfordVaccitech (UK) LimitedUnknownCastration-resistant Prostate Cancer | Intermediate Risk Prostate CancerUnited Kingdom
-
Arno TherapeuticsUnknownRecurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Androgen-independent Prostate CancerUnited Kingdom
-
BayerCompletedBone Metastases | Hormone Refractory Prostate CancerItaly, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
-
Institute of Cancer Research, United KingdomProstate Cancer UKRecruitingCastration-resistant Prostate Cancer | Metastatic Prostate CancerUnited Kingdom
-
ImmuniconUnknownProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
MacroGenicsRecruitingProstate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint MoleculeUnited States, Spain, France, Belgium, United Kingdom, Poland, Georgia, Bulgaria, Puerto Rico, Australia
-
University College, LondonKing's College London; Imperial College London; Medical Research Council; Cancer...Completed
-
University College London HospitalsCompleted
-
The Christie NHS Foundation TrustAstraZenecaCompletedMetastatic Castration Resistant Prostate CancerUnited Kingdom
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeSuspendedProstate Cancer | Prostate NeoplasmUnited Kingdom
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
Barts & The London NHS TrustTerminatedCastrate Resistant Prostate CancerUnited Kingdom
-
Institute of Cancer Research, United KingdomMerck Sharp & Dohme LLCRecruitingCastration-resistant Prostate CancerUnited Kingdom
-
University College, LondonRecruitingProstate Cancer | Prostate NeoplasmUnited Kingdom